Epigenetic Drivers in Pediatric Medulloblastoma

Overview

Journal Cerebellum

Publisher Springer

Specialty Neurology

Date 2017 Nov 28

PMID 29178021

Citations 42

Authors

Martine F Roussel

Jennifer L Stripay

Affiliations

Soon will be listed here.

Abstract

Epigenetics is the process by which gene expression is regulated by events other than alterations of the genome. This includes DNA methylation, histone modifications, chromatin remodeling, microRNAs, and long non-coding RNAs. Methylation of DNA, chromatin remodeling, and histone modifications regulate the chromatin and access of transcription factors to DNA and in turn gene transcription. Alteration of chromatin is now recognized to be deregulated in many cancers. Medulloblastoma is an embryonal tumor of the cerebellum and the most common malignant brain tumor in children, that occurs only rarely in adults. Medulloblastoma is characterized by four major molecularly and histopathologically distinct groups, wingless (WNT), sonic hedgehog (SHH), group 3 (G3), and group 4 (G4), that, except for WNT, are each now subdivided in several subgroups. Gene expression array, next-generation sequencing, and methylation profiling of several hundred primary tumors by several consortia and independent groups revealed that medulloblastomas harbor a paucity of mutations most of which occur in epigenetic regulators, genetic alterations in oncogenes and tumor suppressors, in addition to copy number alterations and chromosome gains and losses. Remarkably, some tumors have no reported mutations, suggesting that some genes required for oncogenesis might be regulated by epigenetic mechanisms which are still to be uncovered and validated. This review will highlight several epigenetic regulators focusing mainly on histone modifiers identified in medulloblastoma.

Citing Articles

AZIN1 level is increased in medulloblastoma and correlates with c-Myc activity and tumor phenotype.

Sesen J, Martinez T, Busatto S, Poluben L, Nassour H, Stone C J Exp Clin Cancer Res. 2025; 44(1):56.

PMID: 39962590 PMC: 11831846. DOI: 10.1186/s13046-025-03274-1.

The Role of Chronic Inflammation in Pediatric Cancer.

Mella C, Tsarouhas P, Brockwell M, Ball H Cancers (Basel). 2025; 17(1.

PMID: 39796780 PMC: 11719864. DOI: 10.3390/cancers17010154.

Long-read sequencing for brain tumors.

Shelton W, Zandpazandi S, Nix J, Gokden M, Bauer M, Ryan K Front Oncol. 2024; 14:1395985.

PMID: 38915364 PMC: 11194609. DOI: 10.3389/fonc.2024.1395985.

Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition.

Shendy N, Bikowitz M, Sigua L, Zhang Y, Mercier A, Khashana Y Nat Commun. 2024; 15(1):3483.

PMID: 38664416 PMC: 11045757. DOI: 10.1038/s41467-024-47102-0.

PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma.

Kumar D, Jain S, Coulter D, Joshi S, Chaturvedi N Cancers (Basel). 2023; 15(24).

PMID: 38136401 PMC: 10741595. DOI: 10.3390/cancers15245855.

References

Kim K, Roberts C . Targeting EZH2 in cancer. Nat Med. 2016; 22(2):128-34. PMC: 4918227. DOI: 10.1038/nm.4036. View

Alimova I, Venkataraman S, Harris P, Marquez V, Northcott P, Dubuc A . Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer. 2012; 131(8):1800-9. PMC: 3375399. DOI: 10.1002/ijc.27455. View

Cavalli F, Remke M, Rampasek L, Peacock J, Shih D, Luu B . Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31(6):737-754.e6. PMC: 6163053. DOI: 10.1016/j.ccell.2017.05.005. View

Vo B, Li C, Morgan M, Theurillat I, Finkelstein D, Wright S . Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Rep. 2017; 18(12):2907-2917. PMC: 5415387. DOI: 10.1016/j.celrep.2017.02.073. View

Li X, Shu Q, Su J, Perlaky L, Blaney S, Lau C . Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005; 4(12):1912-22. DOI: 10.1158/1535-7163.MCT-05-0184. View

Ma J, Li H, Chen X, Yang X, Wang Q, Wu M . Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in vivo and in vitro. Neuropathology. 2012; 33(1):7-16. DOI: 10.1111/j.1440-1789.2012.01318.x. View

Shi J, Vakoc C . The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014; 54(5):728-36. PMC: 4236231. DOI: 10.1016/j.molcel.2014.05.016. View

Bachmann I, Halvorsen O, Collett K, Stefansson I, Straume O, Haukaas S . EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2005; 24(2):268-73. DOI: 10.1200/JCO.2005.01.5180. View

Boyer L, Plath K, Zeitlinger J, Brambrink T, Medeiros L, Lee T . Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006; 441(7091):349-53. DOI: 10.1038/nature04733. View

10.

Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C . The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2007; 122(6):1207-13. DOI: 10.1002/ijc.23283. View

11.

Taylor M, Northcott P, Korshunov A, Remke M, Cho Y, Clifford S . Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2011; 123(4):465-72. PMC: 3306779. DOI: 10.1007/s00401-011-0922-z. View

12.

Sharma S, Kelly T, Jones P . Epigenetics in cancer. Carcinogenesis. 2009; 31(1):27-36. PMC: 2802667. DOI: 10.1093/carcin/bgp220. View

13.

Herz H . Enhancer deregulation in cancer and other diseases. Bioessays. 2016; 38(10):1003-15. PMC: 5160997. DOI: 10.1002/bies.201600106. View

14.

Northcott P, Shih D, Peacock J, Garzia L, Morrissy A, Zichner T . Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012; 488(7409):49-56. PMC: 3683624. DOI: 10.1038/nature11327. View

15.

Murphy B, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S . Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013; 73(23):7068-78. PMC: 3857104. DOI: 10.1158/0008-5472.CAN-13-0927. View

16.

Esteller M . Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-59. DOI: 10.1056/NEJMra072067. View

17.

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

18.

Robinson G, Parker M, Kranenburg T, Lu C, Chen X, Ding L . Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012; 488(7409):43-8. PMC: 3412905. DOI: 10.1038/nature11213. View

19.

Packer R, Gajjar A, Vezina G, Rorke-Adams L, Burger P, Robertson P . Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24(25):4202-8. DOI: 10.1200/JCO.2006.06.4980. View

20.

Schwalbe E, Lindsey J, Nakjang S, Crosier S, Smith A, Hicks D . Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017; 18(7):958-971. PMC: 5489698. DOI: 10.1016/S1470-2045(17)30243-7. View